EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Role of Gut Microbiota in Immune Checkpoint Inhibitor Therapy

Yue-Chun Fu, Bing Pang, Shao-Bo Liang iD

Cell Biology International · 2026

DOI: 10.1002/cbin.70148 ↗

At a glance

Übersichtsarbeit in Cell Biology International, 2026. Written by Yue-Chun Fu and 2 co-authors. Institution: Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Major MEDLINE topics: Immune Checkpoint Inhibitors, Gastrointestinal Microbiome, Neoplasms. Cited 2 times so far (Crossref); 118 references. Funded by: Science and Technology Program of Guangzhou, China, Cultivation Project for National Natural Science Foundation of China from the Third Affiliated Hospital of Sun Yat-sen University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Immune checkpoint inhibitors (ICIs), which have become the primary treatment of carcinomas in recent years, not only bring survival benefits to patients, but also come with various side effects. Studies have shown that different gut microbiota groups have different effects on the efficacy and side effects of ICIs. Here, we summarize the relevant research progress on gut microbiota and the efficacy and side effects of ICIs, explore the mechanisms of the gut microbiota in modulating anticancer immunotherapy and further discuss treatment strategies of how the gut microbiota enhancing the efficacy and reducing side effects of ICIs. This study aims to identify specific gut microbiota as potential biomarkers for ICI treatment to screen for patients who may respond effectively to ICI treatment, thereby improving efficacy and mitigating side effects.

Subjects

MeSH terms (MEDLINE)

Immune Checkpoint InhibitorsGastrointestinal MicrobiomeNeoplasmsHumansAnimalsImmunotherapy

Author keywords

Gut microbiotaImmune checkpoint inhibitorsMechanismsProgrammed death‐ligand 1Side effectsTreatment effect

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Department of Radiation Oncology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

ORCID profiles: Shao-Bo Liang

Funding

  • Science and Technology Program of Guangzhou, China
  • Cultivation Project for National Natural Science Foundation of China from the Third Affiliated Hospital of Sun Yat-sen University

Cite

APA

Fu, Y. C., Pang, B., & Liang, S. B. (2026). Role of Gut Microbiota in Immune Checkpoint Inhibitor Therapy. Cell Biology International. https://doi.org/10.1002/cbin.70148

Vancouver

Fu YC, Pang B, Liang SB. Role of Gut Microbiota in Immune Checkpoint Inhibitor Therapy. Cell Biology International. 2026. doi:10.1002/cbin.70148

BibTeX
@article{Fu2026,
  author = {Fu, Yue-Chun and Pang, Bing and Liang, Shao-Bo},
  title = {Role of Gut Microbiota in Immune Checkpoint Inhibitor Therapy},
  journal = {Cell Biology International},
  year = {2026},
  doi = {10.1002/cbin.70148}
}
Start for free →